Journal: Asaio Journal

Article Title: Candidate Biomarkers YES1, Troponin I, Lactate, and Ammonia for Evaluation of Cardiac Function Post Hypothermic Oxygenated Perfusion

doi: 10.1097/MAT.0000000000002419

Figure Lengend Snippet: Up and down-regulation of all significantly changed organ damage-related proteins during HOPE. ( A ) SMAD1; mothers against decapentaplegic homolog 1, ( B ) ALDH3A1; aldehyde dehydrogenase, dimeric NADP-preferring, ( C ) TOP2B; DNA topoisomerase 2-beta, ( D ) PGF; placenta growth factor, ( E ) ENAH; protein enabled homolog, ( F ) FES; tyrosine-protein kinase Fes/Fps, ( G ) LTA4H; leukotriene A-4 hydrolase, ( H ) FOXO1; forkhead box protein O1, ( I ) CA12; carbonic anhydrase 12, ( J ) PLIN1; perilipin-1, ( K ) YES1; tyrosine-protein kinase Yes, ( L ) MAEA; macrophage erythroblast attacher, ( M ) MAGED1; melanoma-associated antigen D1, ( N ) MAX; protein max, ( O ) FOSB; protein fosB. *, non-adjusted p value of less than 0.05; HOPE, hypothermic machine perfusion; NPX, normalized protein expression; T, time in minutes.

Article Snippet: YES1 (BS-4166R, Bioss antibodies, Woburn, MA) immunohistochemistry (IHC) was performed on 4 μm tissue slides.

Techniques: Expressing

Journal: Asaio Journal

Article Title: Candidate Biomarkers YES1, Troponin I, Lactate, and Ammonia for Evaluation of Cardiac Function Post Hypothermic Oxygenated Perfusion

doi: 10.1097/MAT.0000000000002419

Figure Lengend Snippet: YES1 antibody-positive stained cardiac tissue during hypothermic and normothermic machine perfusion over time. Representative YES1 immunohistochemistry images of three porcine hearts ( A–J ) depict a heterogeneous staining pattern. At baseline (T0; A,D,G ), after 4 hours of HOPE (T4; B,E,H ) and at the end of 4 hours NMP (T240; C,F,J ), YES1 is localized in the cytoplasm of endothelial cells and cardiomyocytes with varying intensity. The tissue architecture in these slides remains intact throughout HOPE and NMP.

Article Snippet: YES1 (BS-4166R, Bioss antibodies, Woburn, MA) immunohistochemistry (IHC) was performed on 4 μm tissue slides.

Techniques: Staining, Immunohistochemistry

Journal: Cancer Cell International

Article Title: miR-133a targets YES1 to reduce cisplatin resistance in ovarian cancer by regulating cell autophagy

doi: 10.1186/s12935-021-02412-x

Figure Lengend Snippet: MiR-133a targets YES1 by binding to the 3′-UTR of YES1. A YES1, TTYH3, CTBP2, YPEL2, and KCTD20 were selected as potential downstream genes regulated by miR-133a by intersection analysis from 3 databases (miRDB, TargetScan, and microRNA). B Among the 5 potential genes, the YES1 expression level was dramatically increased in drug-resistant ovarian cancer tissues compared with primary ovarian cancer tissues. C The predicted miR-133a binding sequence in the 3’UTR of YES1 and the generation of dual-luciferase reporter plasmids of YES1-Wt and YES1-Mut are shown. D Luciferase activity assays were carried out in A2780 cells cotransfected with miR-133a mimic or miR-133a NC and YES1-Wt or YES1-Mut. For comparisons, Student’s t test was performed; *p < 0.05

Article Snippet: Primary antibodies against YES1 (1:1000, ABclonal, A0628), LC3b (1:1000, Abcam, AB192890), and Gapdh (1:5000, Proteintech, 51067-2-AP) were used.

Techniques: Binding Assay, Expressing, Sequencing, Luciferase, Activity Assay

Journal: Cancer Cell International

Article Title: miR-133a targets YES1 to reduce cisplatin resistance in ovarian cancer by regulating cell autophagy

doi: 10.1186/s12935-021-02412-x

Figure Lengend Snippet: YES1 depletion decreases cisplatin sensitivity in ovarian cancer cell lines. A and B YES1 was significantly upregulated at both the mRNA level ( A ) and protein level ( B ) in A2780-DDP and SKOV3-DDP cell lines compared with A2780 and SKOV3 cells, respectively. C and D YES1 mRNA levels ( C ) and protein expression ( D ) were reduced significantly after siRNA targeting YES1 transfection. E Yes1 knockdown increases cisplatin sensitivity in A2780-DDP and SKOV3-DDP cell lines. F and G YES1 mRNA levels ( F ) and protein expression ( G ) were increased significantly after YES1-OE vector transfection. H Yes1 overexpression increases cisplatin resistance in A2780 and SKOV3 cells. For comparisons, Student’s t test was performed; *p < 0.05, **p < 0.01

Article Snippet: Primary antibodies against YES1 (1:1000, ABclonal, A0628), LC3b (1:1000, Abcam, AB192890), and Gapdh (1:5000, Proteintech, 51067-2-AP) were used.

Techniques: Expressing, Transfection, Knockdown, Plasmid Preparation, Over Expression

Journal: Cancer Cell International

Article Title: miR-133a targets YES1 to reduce cisplatin resistance in ovarian cancer by regulating cell autophagy

doi: 10.1186/s12935-021-02412-x

Figure Lengend Snippet: MiR-133a targets YES1 and downregulates its expression. A and B The miR-133a mimic inhibited YES1 expression in SKOV3-DDP and A2780-DDP cells at both the mRNA ( A ) and protein ( B ) levels. C and D MiR-133a inhibitor upregulated YES1 expression in SKOV3 and A2780 cells at both the mRNA ( C ) and protein ( D ) levels. E The miR-133a mimic reduced the YES1 overexpression function induced by YES1-OE, but the miR-133a inhibitor had no effect on the overexpression of YES1 compared with the miR-133a NC + YES1-OE group. F Cotransfection of the YES1-OE vector together with miR-133a mimic transfection antagonized YES1-OE-induced cisplatin resistance. For comparisons, Student’s t test was performed; *p < 0.05, **p < 0.01

Article Snippet: Primary antibodies against YES1 (1:1000, ABclonal, A0628), LC3b (1:1000, Abcam, AB192890), and Gapdh (1:5000, Proteintech, 51067-2-AP) were used.

Techniques: Expressing, Over Expression, Cotransfection, Plasmid Preparation, Transfection

Journal: Cancer Cell International

Article Title: miR-133a targets YES1 to reduce cisplatin resistance in ovarian cancer by regulating cell autophagy

doi: 10.1186/s12935-021-02412-x

Figure Lengend Snippet: YES1 regulates autophagy in cisplatin-resistant ovarian cancer cells. A KEGG pathway enrichment analysis of the top 500 genes with high YES1 expression in the ovarian cancer cohort from TCGA database. B LC3B expression was increased in both A2780-DDP and SKOV3-DDP cells compared with A2780 and SKOV3 cells. C Inhibiting miR-133a significantly enhanced LC3B expression in SKOV3 and A2780 cells. D Transfection with the miR-133a mimic reduced LC3B expression in A2780-DDP and SKOV3-DDP cells. E YES1 knockdown reduces LC3B expression in SKOV3-DDP and A2780-DDP cells. F YES1-OE increases LC3B expression in SKOV3 and A2780 cells. G Autophagic flux was enhanced after transfection with mRFP-GFP-LC3 adenovirus in YES1-OE A2780 cells. H Autophagic flux was decreased after transfection with mRFP-GFP-LC3 adenovirus in siYES1 A2780-DDP cells. I Autophagic antagonist-chloroquine reverses cisplatin resistance caused by YES1-OE in A2780 cells. J The autophagy agonist rapamycin weakens cisplatin sensitivity caused by siYES1 in A2780-DDP cells. For comparisons, Student’s t test was performed; *p < 0.05, **p < 0.01

Article Snippet: Primary antibodies against YES1 (1:1000, ABclonal, A0628), LC3b (1:1000, Abcam, AB192890), and Gapdh (1:5000, Proteintech, 51067-2-AP) were used.

Techniques: Expressing, Transfection, Knockdown

Journal: Cancer Cell International

Article Title: miR-133a targets YES1 to reduce cisplatin resistance in ovarian cancer by regulating cell autophagy

doi: 10.1186/s12935-021-02412-x

Figure Lengend Snippet: YES1 overexpression induces cisplatin resistance by regulating autophagy in vivo. A Nude mice and ovarian tumour tissues from the YES1-NC and YES1-OE groups at Day 14 after cisplatin injection intraperitoneally. B Growth curves of tumours were determined based on tumour size, which was measured every 3 Days (n = 5), and it showed significant differences in tumour volume at Days 7, 11 and 14. C The miR-133a expression showed no difference between the YES1-NC and the YES1-OE groups. D and E The YES1 expression increased at both the mRNA ( D ) and protein levels ( E ) in the YES1-OE group compared with the YES1-NC group. F LC3B expression level of xenograft tumours in the YES1-NC group and YES1-OE group after cisplatin treatment. For comparisons, Student’s t test was performed; *p < 0.05, **p < 0.01, ***p < 0.001

Article Snippet: Primary antibodies against YES1 (1:1000, ABclonal, A0628), LC3b (1:1000, Abcam, AB192890), and Gapdh (1:5000, Proteintech, 51067-2-AP) were used.

Techniques: Over Expression, In Vivo, Injection, Expressing